What sets Sunovion apart
Sunovion isn't a household name. But we're confident that it will be. We believe our approach sets us apart. An approach characterized by two things.
First, we look beyond science for science's sake. We look at our patients' needs, and the needs of the healthcare professionals who care for them and find practical ways of developing better treatments.
Second, our focus on our patients' needs has led us to specialize in two distinct and broad-based areas of treatment. These days, more people in the United States from children to seniors are living with respiratory diseases. We are committed to improving their daily lives and helping to minimize the impact of their condition on their everyday activities.
We are equally committed to people suffering from disorders of the central nervous system. People with these conditions need new, advanced therapies to treat them effectively. And we're working to discover, develop and deliver the treatments they need. Sunovion's targeted discovery and development program has already resulted in several treatments such as Lunesta® (eszopiclone), a medicine that helps people sleep better.
Other development programs under way at Sunovion are focused on treating CNS conditions like anxiety, depression, and epilepsy, and schizophrenia. Latuda® (lurasidone HCl) tablets was approved by the U.S. Food and Drug Administration (FDA) on October 28, 2010 for the treatment of patients with schizophrenia. LATUDA is available by prescription in pharmacies across the United States.
On June 28, 2013, LATUDA received approval by the U.S. FDA for the treatment of adult patients with depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as an adjunctive therapy with lithium or valproate.
On November 8, 2013, the U.S. Food and Drug Administration (FDA) approved Aptiom® (eslicarbazepine acetate) tablets, an antiepileptic drug (AED), for use as adjunctive treatment of partial-onset seizures.
The core principles that guide us at Sunovion are:
Our patients come first
If we do the very best we know how for our patients, and the physicians who care for them, our business will grow.
It isn't innovative if it doesn't get results.
We are relentless in seeking out new and scientifically advanced treatments that deliver what patients and their physicians most want and need from their medicines—products that are effective and safe for them to take.
No one approach has all the answers.
Our products are the result of different approaches: our own in-house drug development programs; refining existing products to enhance their safety and efficacy profiles resulting in unique new medicines; along with strategic acquisition and so-called in-licensing of products developed by others.
We can do more good by specializing.
Sunovion science focuses on two specific treatment areas—the central nervous system and respiratory disorders—rather than trying to be all things to all patients. First, the mind, brain and central nervous system. Second, therespiratory system ranging from allergies to asthma to chronic obstructive pulmonary disease (COPD).
Wellness promotes well being.
Healthy bodies and minds free people enabling them to turn outward and reconnect with family, friends, and the wider world. That's the principle that drives all we do at Sunovion.
In what can be a very complex industry, we have a very simple point of view when it comes to our corporate values. The same qualities we want in our relationships with others, we have to exhibit within our own organization. Just as our products say something about our innovation and research, our values say something about the strength of our people and our commitment to enduring relationships.
At the end of the day, all our values support our overriding commitment to one group of people: our patients. Because ultimately, those patients are what this company is all about.
If you're looking for your next great career opportunity, then you've come to the right place. Sunovion is always looking for talented individuals to join our dynamic team.
- Work/Life Balance
- Culture & Values
- Career Opportunities
- Comp & Benefits
- Senior Management
I have been working at Sunovion full-time (More than 5 years)RecommendsPositive OutlookApproves of CEORecommendsPositive OutlookApproves of CEO
For the psychiatric sales force Sunovion had a Territory ownership feel, positive environment and a mature workforce. This is not like big pharma
Limited product portfolio but a great company with good management. Sales reps are treated well and professionally with a level of maturity lacking in big pharma
Advice to Management
Continue with this style of management and avoid the traps big pharma has fallen into
Getting an Interview
Getting an Interview
- No OfferNegative Experience
I applied online – interviewed at Sunovion.
I applied on line. Waited two weeks then had an HR phone screen. One week later it was a phone screen with the hiring manager. Then two weeks later there was a one on one interview with a number employees.
- Hiring Manager asked a few questions, then when I asked the individual questions they became a tad irate as they didn't seem to fit into what the manager was looking for in a candidate. It was quite odd and I knew right away it wasn't going to be a good fit for either of us. One must remember an interview goes both ways. It is rather disappointing because the company as a whole was one I would definitely work for. Answer Question
Helping people breathe easy and sleep properly are the core of Sunovion (formerly Sepracor). The company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Among its six marketed products are asthma drug Xopenex, insomnia therapy Lunesta, and chronic obstructive pulmonary disease (COPD) treatment Brovana. Sunovion markets its products to primary care physicians and some specialists in the US. It has licensed international development and commercialization rights for Lunesta to Eisai and ...